Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 14 Show results per page	View Search Criteria \| Help With Results


1.		PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care, Treatment				Completed				18 and over				Pharmaceutical / Industry				20050100 NCT00352703


2.		A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Supportive care, Treatment				Closed				18 and over				Pharmaceutical / Industry				20040122 NCT00393822

Last Modified: 2/3/2005 First Published: 7/1/2001


3.		Phase III Randomized Study of Recombinant Human Keratinocyte Growth Factor in Reducing Therapy-Induced Oral Mucositis in Patients With Hematologic Malignancies Undergoing Total Body Irradiation and High-Dose Chemotherapy Followed By Autologous Peripheral Blood Stem Cell Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0012064 AMGEN-KGF-20000162, FHCRC-1612.00, MSKCC-01065, NCI-G01-1961


4.		Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				18 and over				Pharmaceutical / Industry				20020402 NCT00101582


5.		A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Closed				18 and over				Pharmaceutical / Industry				20040118 NCT00131638

Last Modified: 5/27/2008 First Published: 7/25/2006


6.		Phase III Randomized Study of Palifermin for Reducing Oral Mucositis in Patients With Locally Advanced Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Hypopharynx, or Larynx Undergoing Concurrent Radiotherapy and Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Completed				18 and over				NCI				RTOG-0435 RTOG 0435, RTOG-0435, NCT00360971

Last Modified: 12/1/1999 First Published: 2/1/1998


7.		Phase I/II Randomized Study of Recombinant Human Keratinocyte Growth Factor in Patients with Hodgkin's Disease and Non-Hodgkin's Lymphoma Undergoing High Dose Chemotherapy with Autologous Peripheral Blood Stem Cell Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Supportive care, Treatment				Closed				16 and over				Pharmaceutical / Industry				MSKCC-97112 AMGEN-KGF-960189, NCI-G97-1368

Last Modified: 3/1/2000 First Published: 4/1/1998


8.		Phase I/II Randomized Study of Recombinant Human Keratinocyte Growth Factor in Patients With Head and Neck Cancer Undergoing Chemoradiotherapy (Summary Last Modified 03/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				Adult				NCI				RPCI-DS-97-33 AMGEN-KGF-970149-08, NCI-G98-1397


9.		A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Supportive care, Treatment				Temporarily closed				18 and over				Pharmaceutical / Industry				20070201 NCT00540332

Last Modified: 6/1/2007 First Published: 11/1/1999


10.		Phase II Randomized Study of Recombinant Human Keratinocyte Growth Factor in Patients with Hematologic Malignancies Undergoing Total Body Irradiation and High Dose Chemotherapy with Autologous Peripheral Blood Stem Cell Support

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care, Treatment				Closed				18 to 65				NCI, Pharmaceutical / Industry				MSKCC-99029 AMGEN-KGF-980231-04, NCI-G99-1574, NCT00004061

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute